Home › NDC Lookup › Ingredients › Hydrochlorothiazide › 29300-0485-10
Hydrochlorothiazide 12.5 mg Tablet, 1,000-count — NDC 29300-0485-10 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Hydrochlorothiazide 12.5 mg Tablet, 1,000-count — NDC 29300-485-10 (Billing 29300-0485-10)

by Unichem Pharmaceuticals (USA), Inc. · 1000 TABLET in 1 BOTTLE

This is a package of 1,000 tablets of Hydrochlorothiazide 12.5 mg Tablet from Unichem Pharmaceuticals (USA), Inc., marketed since Apr 2025 and currently FDA-listed; retail pharmacies pay about $0.0340 per tablet (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 29300-0485-10
🏷️ FDA NDC (as labeled) 29300-485-10 billing pads the product segment with a zero
This package
Contains1,000-count Cost per ea$0.0340 NADAC Per package$34.00 / 1000 tablets Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.1988/unit · Part D plans $0.0822/unit — full pricing hub ↓
Main listing for product 29300-485 · Also comes in: 100 tablets 29300-485-01
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 29300-485-10
Product NDC 29300-485
11-digit billing NDC 29300048510
NCPDP billing unit EA — each (per item)
RxCUI 197770, 310798, 429503
UNII 0J48LPH2TH
UPC 0329300129014, 0329300128017
Application # ANDA040907
SPL Set ID 33f3b980-b339-4dbf-99bd-05588c2a298c
Established class (EPC) Thiazide Diuretic
Physiologic effect Increased Diuresis
Chemical class Thiazides
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2025-04-03
Route ORAL
Dosage form TABLET
Substance HYDROCHLOROTHIAZIDE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 37600040000303
GCN Seq No 028915
GCN 00842
HICL code 003649
Ingredient (HICL) Hydrochlorothiazide
HIC1 code R
Therapeutic class — broad (HIC1) Kidney/Urinary Tract
HIC2 code R1
Therapeutic class — intermediate (HIC2) Affect Primarily Kidneys/Urinary Tract
HIC3 code R1F
Therapeutic class — specific (HIC3) Thiazide And Related Diuretics
AHFS code 24:36.20.00
AHFS class Thiazide Diuretics (24:36)
FDB label name HYDROCHLOROTHIAZIDE 12.5 MG TB
FDB brand name Hydrochlorothiazide
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 028915
  • GCN: 00842
  • GPI-14 (Medi-Span): 37600040000303
  • HICL (First Databank): 003649
  • AHFS class code: 24:36.20.00
  • RxCUI (RxNorm): 197770
Why two NDCs? The FDA registers this code as 29300-485-10 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 29300-0485-10. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Thiazide Diuretic class.

Pharmacologic class Thiazide Diuretic
Drug family (ATC) Renin-inhibitors, Thiazides, plain
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name HYDROCHLOROTHIAZIDE 12.5 MG TB Ingredient Hydrochlorothiazide
📗 Our plain-language guide HelloPharmacist
  • It lowers high blood pressure, which helps reduce the risk of strokes and heart attacks. Some products, such as Inzirqo and the tablets, are also used for swelling from conditions...
  • Take it by mouth exactly as prescribed, usually once a day. For swelling, your prescriber may have you take it only some days of the week. Food slightly lowers absorption, so ask m...
  • Dizziness, lightheadedness when standing, stomach upset, headache and weakness are the usual ones. Stand up slowly, and be careful with alcohol since it can worsen dizziness. Use s...
  • Call for eye pain or sudden vision changes, severe rash or blistering, trouble breathing, severe stomach pain, yellow skin or eyes, or unusual bruising or infections. Also call for...
📖 Read our full Hydrochlorothiazide guide →
8
Nutrient depletion considerations

Hydrochlorothiazide may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.

An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.034 $34.00 / 1000 tablets
Medicaid paysCMS SDUD · 12 mo $0.1988 $198.80 / 1000 tablets
Medicare drug plans payPart D · Q2 2026 $0.0822 $82.20 / 1000 tablets
NADAC price history (per ea) — tap or hover for the price & month
Dec 2025 Mar 2026 Jun 2026 Sep 2026 $0.041 $0.034
▼ Down 16% over the last 10 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
29300-0485-01 29300-485-01 100 TABLET in 1 BOTTLE $0.0340 / ea $3.40 2025-06-12 — Active
29300-0485-10 You're viewing this Main listing 1000 TABLET in 1 BOTTLE $0.0340 / ea $33.97 2025-06-12 — Active

You're viewing the largest of 2 pack sizes for this product.

This pack effectively ties for the lowest per-ea cost of the 2 priced pack sizes ($0.0340 NADAC).

In Medicaid, this is the most-dispensed pack of this product — about 76% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 1,000-count package — 1000 tablet in 1 bottle.
How does this package differ from NDC 29300-0485-01?
Both are Hydrochlorothiazide 12.5 mg Tablet — the drug itself is identical. This page's package is the 1,000-count one, while NDC 29300-0485-01 is the 100 tablets package.
What NDC number is used to bill for this package of Hydrochlorothiazide 12.5 mg Tablet?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Hydrochlorothiazide 12.5 mg 00172-3444-60 Teva 100 tablets $0.034 AB Availability likely —
Hydrochlorothiazide 12.5 mg 00228-2820-11 Actavis 100 tablets $0.034 AB Availability likely —
Hydrochlorothiazide 12.5 mg 16729-0182-01 Accord 100 tablets $0.034 AB Availability likely —
Hydrochlorothiazide 12.5 mg 23155-0764-01 Heritage 100 tablets $0.034 AB Availability likely —
Hydrochlorothiazide 12.5 mgthis 29300-0485-10 Unichem 1000 tablets $0.034 AB Availability likely —
Hydrochlorothiazide 12.5 mg 62135-0738-90 Chartwell 90 tablets $0.034 AB Availability likely —
Hydrochlorothiazide 12.5 mg 69315-0155-01 Leading 100 tablets $0.034 AB Availability likely —
Hydrochlorothiazide 12.5 mg 00615-8449-39 NCS 30 tablets — AB FDA listed —
Hydrochlorothiazide 12.5 mg 50090-1088-00 A-S 30 tablets — AB FDA listed —
Hydrochlorothiazide 12.5 mg 50090-6372-00 A-S 30 tablets — AB FDA listed —
Hydrochlorothiazide 12.5 mg 50090-6931-00 A-S 90 tablets — AB FDA listed —
Hydrochlorothiazide 12.5 mg 50090-7764-00 A-S 30 tablets — AB FDA listed —
Hydrochlorothiazide 12.5 mg 50090-7765-00 A-S 90 tablets — AB FDA listed —
Hydrochlorothiazide 12.5 mg 50090-7772-00 A-S 30 tablets — AB FDA listed —
Hydrochlorothiazide 12.5 mg 50090-7773-00 A-S 90 tablets — AB FDA listed —
Hydrochlorothiazide 12.5 mg 50090-7817-00 A-S 90 tablets — AB FDA listed —
Hydrochlorothiazide 12.5 mg 51407-0330-01 Golden 100 tablets — AB FDA listed —
Hydrochlorothiazide 12.5 mg 51655-0502-26 Northwind 90 tablets — AB FDA listed —
Hydrochlorothiazide 12.5 mg 51655-0674-26 Northwind 90 tablets — AB FDA listed —
Hydrochlorothiazide 12.5 mg 60760-0662-90 St. 90 tablets — AB FDA listed —
Hydrochlorothiazide 12.5 mg 63187-0553-30 Proficient 30 tablets — AB FDA listed —
Hydrochlorothiazide 12.5 mg 63629-7782-01 Bryant 30 tablets — AB FDA listed —
Hydrochlorothiazide 12.5 mg 67046-1664-03 Coupler 30 tablets — AB FDA listed —
Hydrochlorothiazide 12.5 mg 68071-3443-03 NuCare 30 tablets — AB FDA listed —
Hydrochlorothiazide 12.5 mg 68071-3608-03 NuCare 30 tablets — AB FDA listed —
Hydrochlorothiazide 12.5 mg 68071-3652-01 NuCare 100 tablets — AB FDA listed —
Hydrochlorothiazide 12.5 mg 68788-8813-01 Preferred 7 tablets — AB FDA listed —
Hydrochlorothiazide 12.5 mg 70518-4251-00 REMEDYREPACK 90 tablets — AB FDA listed —
Hydrochlorothiazide 12.5 mg 70518-4466-00 REMEDYREPACK 30 tablets — AB FDA listed —
Hydrochlorothiazide 12.5 mg 71335-9647-01 Bryant 30 tablets — AB FDA listed —
Hydrochlorothiazide 12.5 mg 70518-4736-00 REMEDYREPACK 30 tablets — AB FDA listed —
Hydrochlorothiazide 12.5 mg 53401-0038-53 Aphena 60 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2025
On the market since
Apr 2025
📍
2026
Currently FDA-listed
1 year listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color Orange
ShapeRound
ImprintH1;U
Size6 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII O7TSZ97GEP
    A mineral compound that serves as a filler and binding agent in tablets and capsules. It adds bulk to the medicine and helps hold ingredients together during manufacturing.
  • UNII H77VEI93A8
    A synthetic yellow dye used to color medications. It helps identify the drug and make it visually distinctive, with no effect on how the medicine works.
  • UNII EWQ57Q8I5X
    Lactose monohydrate is a natural sugar derived from milk. It serves as a filler and binder in tablets and capsules, helping create the proper size, texture, and consistency of the medicine.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
  • UNII O8232NY3SJ
    A plant-based carbohydrate derived from corn kernels. It acts as a filler to add bulk, a binder to hold ingredients together, and a disintegrant to help the tablet break apart in your stomach for absorption.

6 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerUnichem Pharmaceuticals (USA), Inc.
Application holderUNICHEM LABORATORIES LTD
FDA applicationANDA040907 (ANDA)
Labeler code29300
First marketedApr 2025
Product typeHuman Prescription Drug
Portfolio210 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ~1 min read ▾

INDICATIONS AND USAGE Hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.

Use in Pregnancy Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy.

Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy (see PRECAUTIONS: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the gravid uterus, is properly treated through elevation of the lower extremities and use of support stockings. Use of diuretics to lower intravascular volume in this instance is illogical and unnecessary.

During normal pregnancy there is hypervolemia which is not harmful to the fetus or the mother in the absence of cardiovascular disease. However, it may be associated with edema, rarely generalized edema. If such edema causes discomfort, increased recumbency will often provide relief.

Rarely this edema may cause extreme discomfort which is not relieved by rest. In these instances, a short course of diuretic therapy may provide relief and be appropriate.

⏱️ Dosage and Administration ~1 min read ▾

DOSAGE AND ADMINISTRATION Therapy should be individualized according to patient response. Use the smallest dosage necessary to achieve the required response. Adults For Edema The usual adult dosage is 25 mg to 100 mg daily as a single or divided dose.

Many patients with edema respond to intermittent therapy, i.e., administration on alternate days or on 3 to 5 days each week. With an intermittent schedule, excessive response and the resulting undesirable electrolyte imbalance are less likely to occur. For Control of Hypertension The usual initial dose in adults is 25 mg daily given as a single dose.

The dose may be increased to 50 mg daily, given as a single or two divided doses. Doses above 50 mg are often associated with marked reductions in serum potassium (see also PRECAUTIONS ). Patients usually do not require doses in excess of 50 mg of hydrochlorothiazide daily when used concomitantly with other antihypertensive agents.

Infants and Children For Diuresis and for Control of Hypertension The usual pediatric dosage is 0.5 mg to 1 mg per pound (1 to 2 mg/kg) per day in single or two divided doses, not to exceed 37.5 mg per day in infants up to 2 years of age or 100 mg per day in children 2 to 12 years of age. In infants less than 6 months of age, doses up to 1.5 mg per pound (3 mg/kg) per day in two divided doses may be required. (See PRECAUTIONS: Pediatric Use .)

⛔ Contraindications 11 words ▾

CONTRAINDICATIONS Anuria. Hypersensitivity to this product or to other sulfonamide-derived drugs.

⚠️ Warnings 209 words ▾

WARNINGS Use with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function.

Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. Thiazides may add to or potentiate the action of other antihypertensive drugs. Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma.

The possibility of exacerbation or activation of systemic lupus erythematosus has been reported. Lithium generally should not be given with diuretics (see PRECAUTIONS, Drug Interactions ). Acute Myopia and Secondary Angle-Closure Glaucoma Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma.

Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible.

Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.

🤒 Adverse Reactions ~1 min read ▾

ADVERSE REACTIONS The following adverse reactions have been reported and, within each category, are listed in order of decreasing severity. Body as a Whole: Weakness. Cardiovascular: Hypotension including orthostatic hypotension (may be aggravated by alcohol, barbiturates, narcotics or antihypertensive drugs).

Digestive: Pancreatitis, jaundice (intrahepatic cholestatic jaundice), diarrhea, vomiting, sialadenitis, cramping, constipation, gastric irritation, nausea, anorexia. Hematologic: Aplastic anemia, agranulocytosis, leukopenia, hemolytic anemia, thrombocytopenia. Hypersensitivity: Anaphylactic reactions, necrotizing angiitis (vasculitis and cutaneous vasculitis), respiratory distress including pneumonitis and pulmonary edema, photosensitivity, fever, urticaria, rash, purpura.

Metabolic: Electrolyte imbalance (see PRECAUTIONS ), hyperglycemia, glycosuria, hyperuricemia. Musculoskeletal: Muscle spasm. Nervous System/Psychiatric: Vertigo, paresthesias, dizziness, headache, restlessness.

Renal: Renal failure, renal dysfunction, interstitial nephritis (see WARNINGS ). Skin: Erythema multiforme including Stevens-Johnson Syndrome, exfoliative dermatitis including toxic epidermal necrolysis, alopecia. Special Senses: Transient blurred vision, xanthopsia.

Urogenital: Impotence. Whenever adverse reactions are moderate or severe, thiazide dosage should be reduced or therapy withdrawn. Postmarketing Experience: Non-melanoma Skin Cancer Hydrochlorothiazide is associated with an increased risk of non-melanoma skin cancer.

In a study conducted in the Sentinel System, increased risk was predominantly for squamous cell carcinoma (SCC) and in white patients taking large cumulative doses. The increased risk for SCC in the overall population was approximately 1 additional case per 16,000 patients per year, and for white patients taking a cumulative dose of ≥ 50,000 mg the risk increase was approximately 1 additional SCC case for every 6,700 patients per year.

🔄 Drug Interactions 218 words ▾

Drug Interactions When given concurrently the following drugs may interact with thiazide diuretics. Alcohol, barbiturates, or narcotics Potentiation of orthostatic hypotension may occur. Antidiabetic drugs (oral agents and insulin) Dosage adjustment of the antidiabetic drug may be required.

Other antihypertensive drugs Additive effect or potentiation. Cholestyramine and colestipol resins Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.

Corticosteroids, ACTH Intensified electrolyte depletion, particularly hypokalemia. Pressor amines (e.g., norepinephrine) Possible decreased response to pressor amines but not sufficient to preclude their use. Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine) Possible increased responsiveness to the muscle relaxant.

Lithium Generally should not be given with diuretics. Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity. Refer to the package insert for lithium preparations before use of such preparations with hydrochlorothiazide.

Non-steroidal Anti-inflammatory Drugs In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when hydrochlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.

🤰 Pregnancy 107 words ▾

Pregnancy Teratogenic Effects-Pregnancy Category B Studies in which hydrochlorothiazide was orally administered to pregnant mice and rats during their respective periods of major organogenesis at doses up to 3000 and 1000 mg hydrochlorothiazide/kg, respectively, provided no evidence of harm to the fetus. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nonteratogenic Effects Thiazides cross the placental barrier and appear in cord blood. There is a risk of fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions that have occurred in adults.

🧒 Pediatric Use 48 words ▾

Pediatric Use There are no well controlled clinical trials in pediatric patients. Information on dosing in this age group is supported by evidence from empiric use in pediatric patients and published literature regarding the treatment of hypertension in such patients. (See DOSAGE AND ADMINISTRATION: Infants and Children .)

🆘 Overdosage 104 words ▾

OVERDOSAGE The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias. In the event of overdosage, symptomatic and supportive measures should be employed.

Emesis should be induced or gastric lavage performed. Correct dehydration, electrolyte imbalance, hepatic coma and hypotension by established procedures. If required, give oxygen or artificial respiration for respiratory impairment.

The degree to which hydrochlorothiazide is removed by hemodialysis has not been established. The oral LD 50 of hydrochlorothiazide is greater than 10 g/kg in the mouse and rat.

🧬 Clinical Pharmacology 152 words ▾

CLINICAL PHARMACOLOGY The mechanism of the antihypertensive effect of thiazides is unknown. Hydrochlorothiazide does not usually affect normal blood pressure. Hydrochlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption.

At maximal therapeutic dosage all thiazides are approximately equal in their diuretic efficacy. Hydrochlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate.

After oral use diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours. Pharmacokinetics and Metabolism Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.

At least 61 percent of the oral dose is eliminated unchanged within 24 hours. Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.

📦 How Supplied / Storage and Handling ~1 min read ▾

HOW SUPPLIED Hydrochlorothiazide Tablets, USP are available as light orange, mottled, circular, flat, beveled, uncoated tablets, debossed with "H1" on one side and "U" on other side containing 12.5 mg of hydrochlorothiazide, USP. Bottles of 100 : NDC 29300-485-01 Bottles of 1,000 : NDC 29300-485-10 Hydrochlorothiazide Tablets, USP are available as light orange, circular, flat, beveled, uncoated tablets, with score line having "U" and "128" debossed across the score line on one side and plain on other side containing 25 mg of hydrochlorothiazide, USP.

Bottles of 100 : NDC 29300-128-01 Bottles of 500 : NDC 29300-128-05 Bottles of 1,000 : NDC 29300-128-10 Bottles of 5,000 : NDC 29300-128-50 Hydrochlorothiazide Tablets, USP are available as light orange, circular, flat, beveled, uncoated tablets, with score line having "U" and "129" debossed across the score line on one side and plain on other side containing 50 mg of hydrochlorothiazide, USP. Bottles of 100 : NDC 29300-129-01 Bottles of 500 : NDC 29300-129-05 Bottles of 1,000 : NDC 29300-129-10 Bottles of 5,000 : NDC 29300-129-50 PHARMACIST: Dispense in a well-closed container as defined in the USP.

Use child-resistant closure (as required) Store at 20° to 25° C (68° to 77° F) [see USP Controlled Room Temperature]. KEEP THIS AND ALL DRUGS OUT OF REACH OF CHILDREN. Please address medical inquiries to Unichem's toll free # 1-866-562-4616.

Manufactured by: UNICHEM LABORATORIES LTD. Pilerne Ind. Estate, Pilerne, Bardez, Goa 403 511, India Manufactured for: East Brunswick, NJ 08816 09-R-05/2025 13014161 Company Logo

📋 Description 120 words ▾

DESCRIPTION Hydrochlorothiazide, USP is a diuretic and antihypertensive. It is the 3, 4-dihydro derivative of chlorothiazide. It is chemically designated as 6-chloro-3, 4-dihydro-2 H -1, 2, 4- benzothiadiazine-7-sulfonamide 1, 1-dioxide and has the following structural formula: Hydrochlorothiazide, USP is a white, or practically white, crystalline powder which is slightly soluble in water, freely soluble in sodium hydroxide solution, in n-butylamine, and in dimethylformamide; sparingly soluble in methanol; insoluble in ether, in chloroform, and in dilute mineral acids.

Each tablet for oral administration contains 12.5 mg, 25 mg or 50 mg hydrochlorothiazide, USP. In addition, each tablet contains the following inactive ingredients: corn starch, FD&C Yellow #6, dibasic calcium phosphate, pregelatinized starch, colloidal silicon dioxide, lactose monohydrate and magnesium stearate. Hydrochlorothiazide

💬 Information for Patients 22 words ▾

Information for Patients Non-melanoma Skin Cancer: Instruct patients taking hydrochlorothiazide to protect skin from the sun and undergo regular skin cancer screening.

⚠️ Precautions ~2 min read ▾

PRECAUTIONS General All patients receiving diuretic therapy should be observed for evidence of fluid or electrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia. Serum and urine electrolyte determinations are particularly important when the patient is vomiting excessively or receiving parenteral fluids. Warning signs or symptoms of fluid and electrolyte imbalance, irrespective of cause, include dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, confusion, seizures, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting.

Hypokalemia may develop, especially with brisk diuresis, when severe cirrhosis is present or after prolonged therapy. Interference with adequate oral electrolyte intake will also contribute to hypokalemia. Hypokalemia may cause cardiac arrhythmia and may also sensitize or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased ventricular irritability).

Hypokalemia may be avoided or treated by use of potassium sparing diuretics or potassium supplements such as foods with a high potassium content. Although any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or renal disease), chloride replacement may be required in the treatment of metabolic alkalosis. Dilutional hyponatremia may occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt, except in rare instances when the hyponatremia is life threatening.

In actual salt depletion, appropriate replacement is the therapy of choice. Hyperuricemia may occur or acute gout may be precipitated in certain patients receiving thiazides. In diabetic patients dosage adjustments of insulin or oral hypoglycemic agents may be required.

Hyperglycemia may occur with thiazide diuretics. Thus latent diabetes mellitus may become manifest during thiazide therapy. The antihypertensive effects of the drug may be enhanced in the post-sympathectomy patient.

If progressive renal impairment becomes evident, consider withholding or discontinuing diuretic therapy. Thiazides have been shown to increase the urinary excretion of magnesium; this may result in hypomagnesemia. Thiazides may decrease urinary calcium excretion.

Thiazides may cause intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Marked hypercalcemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.

Increases in cholesterol and triglyceride levels may be associated with thiazide diuretic therapy. Information for Patients Non-melanoma Skin Cancer: Instruct patients taking hydrochlorothiazide to protect skin from the sun and undergo regular skin cancer screening. Laboratory Tests Periodic determination of serum electrolytes to detect possible electrolyte imbalance should be done at appropriate intervals.

Drug Interactions When given concurrently the following drugs may interact with thiazide diuretics. Alcohol, barbiturates, or narcotics Potentiation of orthostatic hypotension may occur. Antidiabetic drugs (oral agents and insulin) Dosage adjustment of the antidiabetic drug may be required.

Other antihypertensive drugs Additive effect or potentiation. Cholestyramine and colestipol resins Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.

Corticosteroids, ACTH Intensified electrolyte depletion, particularly hypokalemia. Pressor amines (e.g., norepinephrine) Possible decreased response to pressor amines but not sufficient to preclude their use. Skeletal mu… [Excerpted — this section continues on DailyMed.]

🍼 Nursing Mothers 43 words ▾

Nursing Mothers Thiazides are excreted in breast milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue hydrochlorothiazide, taking into account the importance of the drug to the mother.

📄 Package Label / Principal Display Panel 24 words ▾

PRINCIPAL DISPLAY PANEL Hydrochlorothiazide Tablets USP 12.5 mg Hydrochlorothiazide Tablets USP 25 mg Hydrochlorothiazide Tablets USP 50 mg Container Label Container Label Container Label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q3 2025 – Q1 2026 · 3 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
13.8K
Units reimbursed last 4 qtrs
544.9K
Gross reimbursed last 4 qtrs
$108.3K
Avg / prescription
$7.84
Avg / unit
$0.1988
Latest quarter Q1 2026
10.7KRx
Medicaid pays / ea
$0.1988
gross reimbursed
vs
NADAC / ea
$0.0340
acquisition cost
=
Spread
+$0.1648
+485% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
22% FFS 78% MCO
Fee-for-service · 3,002 Rx Managed care · 10,817 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: 12,797 units · 164 per 100k residents WA Idaho: 1,080 units · 55.0 per 100k residents ID Montana: 1,388 units · 123 per 100k residents MT North Dakota: no data reported ND Minnesota: 10,147 units · 177 per 100k residents MN Wisconsin: 4,115 units · 69.6 per 100k residents WI Michigan: 16,568 units · 165 per 100k residents MI New York: 42,211 units · 216 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 17,238 units · 407 per 100k residents OR Nevada: 3,557 units · 111 per 100k residents NV Wyoming: no data reported WY South Dakota: 4,816 units · 524 per 100k residents SD Iowa: 4,680 units · 146 per 100k residents IA Illinois: 6,808 units · 54.3 per 100k residents IL Indiana: 6,577 units · 95.8 per 100k residents IN Ohio: 38,171 units · 324 per 100k residents OH Pennsylvania: 28,449 units · 219 per 100k residents PA New Jersey: 9,219 units · 99.2 per 100k residents NJ Massachusetts: 3,796 units · 54.2 per 100k residents MA California: no data reported CA Utah: no data reported UT Colorado: 3,605 units · 61.3 per 100k residents CO Nebraska: 1,904 units · 96.3 per 100k residents NE Missouri: 14,156 units · 228 per 100k residents MO Kentucky: 43,933 units · 971 per 100k residents KY West Virginia: 7,960 units · 450 per 100k residents WV Virginia: 14,371 units · 165 per 100k residents VA Maryland: 7,334 units · 119 per 100k residents MD Connecticut: 3,159 units · 87.3 per 100k residents CT Rhode Island: 689 units · 62.9 per 100k residents RI Arizona: 840 units · 11.3 per 100k residents AZ New Mexico: 4,333 units · 205 per 100k residents NM Kansas: 1,529 units · 52.0 per 100k residents KS Arkansas: 9,946 units · 324 per 100k residents AR Tennessee: 5,876 units · 82.5 per 100k residents TN North Carolina: 23,796 units · 220 per 100k residents NC South Carolina: 4,068 units · 75.7 per 100k residents SC Delaware: 810 units · 78.6 per 100k residents DE Oklahoma: 3,865 units · 95.4 per 100k residents OK Louisiana: 10,287 units · 225 per 100k residents LA Mississippi: 4,422 units · 150 per 100k residents MS Alabama: 4,085 units · 80.0 per 100k residents AL Georgia: 6,374 units · 57.8 per 100k residents GA D.C.: no data reported DC Hawaii: 1,800 units · 125 per 100k residents HI Texas: 15,035 units · 49.3 per 100k residents TX Florida: 15,375 units · 68.0 per 100k residents FL
Units reimbursed · per 100k residents
11.3971
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Kentucky 971 /100k
2 South Dakota 524 /100k
3 West Virginia 450 /100k
4 Oregon 407 /100k
5 Arkansas 324 /100k
6 Ohio 324 /100k
7 Missouri 228 /100k
8 Louisiana 225 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1000 tablets this page29300-0485-10 13,819 Rx · $108,336
100 tablets29300-0485-01 4,458 Rx · $43,074
Drug total (last 4 qtrs): 18,277 Rx · 722,712 units · $151,410 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Hydrochlorothiazide — the program that covers self-administered drugs. 17 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Hydrochlorothiazide. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$20.24M
Claims incl. refills
4.4M
Beneficiaries
3.6M
Spend / beneficiary
$5.65
Spend / claim
$4.63
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.